Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validated Automated Cuff Blood Pressure Devices for Children: STRIDE BP Report and Call to Action.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

Central Systolic Blood Pressure and Left Ventricular Mass: Findings From the International 24-Hour Aortic Blood Pressure Consortium.

Journal of the American Heart Association·2026
Same author

Hypertension and cardiometabolic multimorbidity: an analysis of 3.4 million participants from the global May Measurement Month blood pressure screening campaign.

BMJ public health·2026
Same author

Single Interventions (Pharmacological or Renal Denervation) Are Not Sufficient to Achieve Blood Pressure Control in Resistant Hypertension: A Systematic Review and Meta-Analysis.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

Novel hypertension phenotypes based on cross-classification of 24-h brachial and aortic SBP.

Journal of hypertension·2026
Same author

Impact of lipid-lowering treatment on the performance of SCORE2 algorithms in detecting high-risk individuals.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2026

Related Experiment Videos

Combination pharmacotherapy in hypertension.

George S Stergiou1

  • 1Hypertension Center, Third University Department of Medicine, Sotiria Hospital, 152 Mesogion Avenue, Athens, 11527, Greece. gstergi@med.uoa.gr

International Urology and Nephrology
|November 24, 2006
PubMed
Summary

Achieving blood pressure goals often requires combination pharmacotherapy. Combining two or more antihypertensive drugs can improve efficacy, reduce side effects, and enhance patient compliance for better hypertension management.

Related Experiment Videos

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Most hypertensive patients require combination pharmacotherapy to achieve blood pressure goals, especially <130/80 mm Hg.
  • Combination therapy offers potentiated antihypertensive effects, potentially fewer adverse effects, and improved patient compliance.

Purpose of the Study:

  • To review the role and benefits of combination pharmacotherapy in managing hypertension.
  • To discuss guideline recommendations for initiating combination therapy, including in patients with significant blood pressure elevation and complications.

Main Methods:

  • Review of current guidelines and available antihypertensive drug classes.
  • Discussion of principles for selecting antihypertensive agents based on first-line recommendations and compelling indications.
  • Consideration of potential long-term metabolic effects of specific drug combinations.

Main Results:

  • Combination therapy is essential for the majority of patients to reach target blood pressure.
  • Guidelines support initial combination therapy for patients with severe hypertension and complications.
  • Multiple effective antihypertensive drug classes allow for various combination options.

Conclusions:

  • Intensive up-titration and systematic use of full-dose combination therapy are expected to optimize blood pressure control in most hypertensive patients.
  • Further outcome data comparing different antihypertensive drug combinations are needed.
  • Choice of combination should consider first-line drugs, compelling indications, and potential metabolic effects.